AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6196841
Drug: Cefotaxime (Claforan)
RxNorm normalized name: cefotaxime Injection [Claforan]
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (Claforan) given peroperatively and daily for five days
Trial: 6196841
Drug: Methenamine (Hiprex)
RxNorm normalized name: Methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine (Hiprex) given daily from the day before the operation for a total of six days
Trial: 30318332
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 mL normal saline)
Trial: 31117092
Drug: Biological graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological graft
Trial: 22906114
Drug: Early orthodontic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early orthodontic treatment (initial maxillary expansion and subsequent activator therapy)
Trial: 22906114
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no early orthodontic treatment)
Trial: 12394122
Drug: Radioactive iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radioactive iodine treatment (I-131)
Trial: 9920085
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (200 mg/week)
Trial: 7755384
Drug: AO-90 (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-90 (500-750 mL/day)
Trial: 7755383
Drug: C/MF (Amiparen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/MF (Amiparen, 600-800 mL/day)
Trial: 30772866
Drug: Topical intranasal
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intranasal tranexamic acid (TXA)
Trial: 27995674
Drug: Cognitive Analytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Analytic Therapy (CAT), 24 sessions
Trial: 21178181
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (0.052 µg•kg of BW(‐1)•d(‐1))
Trial: 21178181
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (0.103 µg•kg of BW(‐1)•d(‐1))
Trial: 21178181
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (0.155 µg•kg of BW(‐1)•d(‐1))
Trial: 21178181
Drug: CCK infusion
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK infusion (0.069 µg•kg of BW(‐1)•d(‐1))
Trial: 21178181
Drug: CCK infusion
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK infusion (0.138 µg•kg of BW(‐1)•d(‐1))
Trial: 21178181
Drug: CCK infusion
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK infusion (0.207 µg•kg of BW(‐1)•d(‐1))
Trial: 21178181
Drug: CCK infusion
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK infusion
Trial: 18515460
Drug: Aripiprazole (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (5-15 mg)
Trial: 7774313
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metaproterenol aerosol pretreatment
Trial: 7774313
Drug: No bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bronchodilator
Trial: 3291110
Drug: Ribomunyl aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ribomunyl aerosol and injections (n = 17)
Trial: 30633776
Drug: 2012 RCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2012 RCT preparation costs
Trial: 30633776
Drug: 2016 RCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2016 RCT preparation costs
Trial: 29231500
Drug: Tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin hydrochloride sustained-release capsules, 0.2 mg, once a day for 6 weeks.
Trial: 26619557
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg desloratadine tablets
Trial: 18071677
Drug: CCKb receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCKb receptor agonist pentagastrin (0.1 microg/kg)
Trial: 18071677
Drug: mu-opioid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mu-opioid receptor agonist remifentanil (0.0625 microg/kg)
Trial: 14587169
Drug: Oral glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycoprotein IIb/IIIa receptor antagonists
Trial: 15239621
Drug: Sirolimus (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (target trough level 10-15 ng/mL)
Trial: 8573755
Drug: Intensified care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified care (IC) - hypertension teaching and treatment program based on blood pressure self-monitoring
Trial: 8573755
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care (RC) - routine antihypertensive therapy
Trial: 2232966
Drug: Combined chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemo-immunotherapy with thymopentin
Trial: 2232966
Drug: Only chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only chemotherapy
Trial: 326097
Drug: Pyridinolcarbamate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridinolcarbamate (1.5 g thrice daily for 4 weeks)
Trial: 326097
Drug: Inositol niacinate
RxNorm normalized name: Inositol niacinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol niacinate (1.2 g thrice daily for 4 weeks)
Trial: 326097
Drug: Pyridinolcarbamate (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridinolcarbamate (1.5 g thrice daily for 6 weeks)
Trial: 326097
Drug: Inositol niacinate
RxNorm normalized name: Inositol niacinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol niacinate (1.2 g thrice daily for 6 weeks)
Trial: 25997115
Drug: PF-04958242 (0.27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04958242 (0.27 mg)
Trial: 25997115
Drug: PF-04958242 (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04958242 (0.35 mg)
Trial: 7527107
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg/day
Trial: 7527107
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of trandolapril 2 mg/day and HCTZ 25 mg/day
Trial: 2501093
Drug: GTN patch
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN patch (7.5 mg GTN (24h)‐1)
Trial: 19199105
Drug: Standard decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard decongestive lymphatic therapy (DLT) with pneumatic compression (PC) (bandage group, N = 21)
Trial: 1636712
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline (control)
Trial: 7871360
Drug: Miconazole 55
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole 55 mg/g denture lacquer applied once on the mucosal denture surface
Trial: 31072195
Drug: L-shaped silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-shaped silicone prosthesis (group A)
Trial: 28350759
Drug: Trans-resveratrol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol (75 mg, twice daily)
Trial: 24353564
Drug: Mat Pilates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mat Pilates exercise program (8 weeks, 3 times weekly)
Trial: 21685641
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure therapy (VRET)
Trial: 18544984
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg
Trial: 9797850
Drug: CRH administration
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH administration (100 micrograms hCRH)
Trial: 7658052
Drug: maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintenance therapy
Trial: 2732449
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha (rIFN alpha)‐2A, administered intramuscularly in doses ranging from 1.5 MU to 20 MU/m2 of body surface, two or three times weekly during 4‐6 months.
Trial: 22298121
Drug: Riluzole (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (100-200 mg/day)
Trial: 18983318
Drug: Immediate restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate restoration of single implants placed at the time of tooth extraction (test group)
Trial: 18983318
Drug: Immediate restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate restoration of single implants placed 8 weeks after tooth extraction (control group)
Trial: 16098300
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors during TAXUS stent implantation
Trial: 16098300
Drug: Control stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control stent without GP IIb/IIIa inhibitors
Trial: 8934156
Drug: Urea-gel method
RxNorm normalized name: urea Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea-gel method
Trial: 6384289
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical minoxidil for 12 months
Trial: 6384289
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical minoxidil for 12 months
Trial: 31129108
Drug: Subjective sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective sleep parameters (PSQI-sleep medication)
Trial: 24742124
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (M) 2 g/d
Trial: 24742124
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Oral Contraceptive Pills (M+OCP)
Trial: 22883485
Drug: cART containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cART containing Tenofovir and a non-nucleoside reverse-transcriptase-inhibitor (TFV/NNRTI)
Trial: 22883485
Drug: cART containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cART containing Tenofovir and a protease-inhibitor (TFV/PI)
Trial: 11744653
Drug: Sublingual cyclodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual cyclodextrin androstenediol (Sl Diol) 20 mg
Trial: 8547937
Drug: Feeding 2
RxNorm normalized name: TUBE FEEDING 24FR Y-PORT AMT#4-2402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeding 2 (69 g CHO/400 ml)
Trial: 6342168
Drug: Saline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1 ml)
Trial: 6412271
Drug: Sulpiride morning
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride morning only dose
Trial: 6412271
Drug: Sulpiride daily
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride daily total dose in two equal fractions at 8 a.m. and 4 p.m.
Trial: 29061504
Drug: S‐1 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 therapy
Trial: 21562067
Drug: saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 2.5 mg + glyburide 7.5 mg
Trial: 21562067
Drug: saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 5 mg + glyburide 7.5 mg
Trial: 21562067
Drug: saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saxagliptin 2.5 mg
Trial: 16549457
Drug: L-[1-(13C)]leucine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-[1-(13C)]leucine at 65 mg/(kg.d)
Trial: 16549457
Drug: L-[1-(13C)]leucine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-[1-(13C)]leucine at 45 mg/(kg.d)
Trial: 16549457
Drug: L-[1-(13C)]lysine (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-[1-(13C)]lysine (control)
Trial: 10681363
Drug: Delavirdine (DLV)
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delavirdine (DLV) monotherapy
Trial: 9196609
Drug: Dexfenfluramine (dF)
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine (dF) 15 mg twice daily for 7 days
Trial: 9196609
Drug: Corticotropin releasing
RxNorm normalized name: Corticotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin releasing hormone (CRH) (1 microgram/kg i.v.)
Trial: 8453437
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg, three times a day for six weeks)
Trial: 3743143
Drug: Intranasal occlusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal occlusion with petrolatum gauze
Trial: 3743143
Drug: Intranasal occlusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal occlusion
Trial: 26547424
Drug: S‐1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 plus paclitaxel (daily oral S‐1 at 80 mg/m² for 2 weeks plus paclitaxel at 50 mg/m² on days 1 and 8, every 3 weeks)
Trial: 26547424
Drug: Paclitaxel (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (weekly administration at 80 mg/m² three times every 4 weeks)
Trial: 17925000
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no treatment (controls)
Trial: 15717139
Drug: Cisapride 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 0.3 mg/kg daily
Trial: 15717139
Drug: Cisapride 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 0.6 mg/kg daily
Trial: 15717139
Drug: Cisapride treatment
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride treatment
Trial: 9393335
Drug: Whole-cell DTP
RxNorm normalized name: ActHIB with Whole-Cell DTP Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell DTP vaccine (n = 20,720)
Trial: 9393335
Drug: Five-component acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-component acellular DTP vaccine (n = 20,747)
Trial: 9393335
Drug: Three-component acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-component acellular DTP vaccine (n = 20,728)
Trial: 9393335
Drug: Two-component acellular
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-component acellular DTP vaccine (n = 20,697)
Trial: 7514842
Drug: PPSA (polyclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPSA (polyclonal antibodies)
Trial: 7514842
Drug: MPSA (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPSA (monoclonal antibodies)
Trial: 3605184
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg per day of warfarin for 18 months
Trial: 10651597
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and standardized knee exercise program
Trial: 30472808
Drug: Nonusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers of proton pump inhibitors
Trial: 26662809
Drug: Multi-dimensional Treatment
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dimensional Treatment Foster Care (MTFC)
Trial: 24436354
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (70 mL of concentrated beetroot juice containing a minimum of 0.3 g of nitrate)
Trial: 24436354
Drug: Placebo (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (70 mL of placebo)
Trial: 22810982
Drug: MNP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNP group (maize porridge with multi-micronutrient powder containing 2.5 mg iron as NaFeEDTA; 6.6 mg iron/meal)
Trial: 22810982
Drug: Amaranth group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amaranth group (unrefined maize 30% and amaranth grain 70% porridge; 23 mg iron/meal)
Trial: 22810982
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (unrefined maize porridge; 4.1 mg iron/meal)
Trial: 20599002
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day and Ezetimibe 10 mg/day
Trial: 16920077
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (1.5 g/d; .84 g/d eicosapentaenoic acid, .7 g/d docosahexaenoic acid)
Trial: 16247531
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on ZEEPe
Trial: 16247531
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol (10 mg/4 mL) via jet nebulizer for 30 min on PEEPe
Trial: 16247531
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PEEPe and fenoterol
Trial: 12453332
Drug: Capecitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1250 mg/m2 twice daily for 14 days, every 3 weeks)
Trial: 7887554
Drug: Trimethoprim‐sulfamethoxazole (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim‐sulfamethoxazole (one double‐strength tablet daily, five times a week)
Trial: 2487803
Drug: Captopril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (100 mg)
Trial: 2487803
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 mg) + Captopril (50 mg)
Trial: 775145
Drug: ampicillin‐cloxacillin (Rectocillin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampicillin‐cloxacillin (Rectocillin) 1 g/day
Trial: 775145
Drug: ampicillin (AB‐PC)
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ampicillin (AB‐PC) 1 g/day
Trial: 31996367
Drug: ETN administered
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN administered first line
Trial: 31094901
Drug: Intravenous vortioxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vortioxetine 17 mg
Trial: 28067119
Drug: ATV 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV 400 mg daily (switch)
Trial: 28067119
Drug: ATV/r 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/r 300/100 mg daily (control)
Trial: 17692718
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg QD
Trial: 17692718
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (BIS) 2.0 mg BID
Trial: 17692718
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (BIS) 1.0 mg BID
Trial: 11704494
Drug: Inactive ultrasound
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ultrasound (US) treatment
Trial: 3660329
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acids supplementation (2.880 g/day for 12 weeks)
Trial: 29614582
Drug: Bifidobacterium tetragenous
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium tetragenous viable bacteria tablets
Trial: 21621252
Drug: Escalating doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of omega-3 PUFA (1 to 8 g daily over 24 weeks)